How should dizziness and headache be evaluated and managed in a reproductive‑age woman after a medroxyprogesterone acetate depot (Depo‑Provera) injection?

Evaluation and Management of Dizziness and Headache in Women Using Depo-Provera

Headache and dizziness are recognized common side effects of depot medroxyprogesterone acetate (DMPA/Depo-Provera), and while they typically do not indicate serious pathology, you must systematically rule out dangerous conditions before attributing symptoms to the contraceptive. 1

Initial Assessment: Rule Out Serious Pathology

First, immediately evaluate for warning signs that require urgent intervention:

• Stroke symptoms: Sudden severe headache with vomiting, visual changes, speech problems, weakness, or numbness in extremities 1
• Thromboembolic events: Severe unilateral leg pain/swelling (DVT), chest pain with shortness of breath (PE) 1
• Vision loss: Sudden blindness or partial vision loss (retinal vessel thrombosis) 1
• Migraine with aura: New-onset migraines or worsening of pre-existing migraines 1

If any of these are present, discontinue DMPA immediately and manage the acute condition.

Secondary Evaluation: Common DMPA-Related Considerations

If serious pathology is excluded, recognize that headache, dizziness, weakness, tiredness, and nervousness are among the most common side effects reported in clinical trials 1. The FDA label explicitly lists these as frequent adverse effects that may or may not resolve with continued use.

Specific Clinical Factors to Assess:

• Timing: When did symptoms start relative to injection? (symptoms typically emerge early in use)
• Severity: Are symptoms interfering with daily activities or quality of life?
• Pregnancy status: Rule out pregnancy if clinically indicated, especially if injection timing is delayed 2
• Bleeding patterns: Irregular bleeding is nearly universal initially and may contribute to symptoms 2
• Weight changes: Assess for significant weight gain (>5% baseline weight), which predicts continued gain and may correlate with other side effects 3, 2

Management Algorithm

If Symptoms Are Mild and Tolerable:

1. Provide reassurance that headache and dizziness are common, recognized side effects 1
2. Counsel on expected timeline: Many side effects improve with continued use over the first year 3
3. Symptomatic treatment: NSAIDs for headache as needed
4. Monitor: Schedule follow-up to reassess symptom burden

If Symptoms Are Moderate to Severe or Unacceptable to Patient:

Offer method discontinuation and transition to alternative contraception 2. This is a patient-centered decision—if the woman finds the side effects unacceptable, continuing DMPA compromises her quality of life and risks contraceptive discontinuation without a backup method.

Alternative contraceptive options to discuss:

• Progestin-only pills: Lower systemic progestin exposure, though headache can still occur 3
• Levonorgestrel IUD: Primarily local progestin effect, minimal systemic absorption, excellent continuation rates 4
• Copper IUD: Non-hormonal option if hormonal side effects are problematic 4
• Etonogestrel implant: Different progestin formulation that may be better tolerated 5

Critical Pitfalls to Avoid

1. Don't dismiss symptoms as "just side effects" without proper evaluation: The FDA label specifically warns about stroke, blood clots, and vision problems presenting with headache and dizziness 1

2. Don't force continuation: The 2013 CDC guidelines emphasize that if side effects persist and are unacceptable to the patient, you should counsel on alternatives and offer another method 2. Patient autonomy and quality of life take precedence.

3. Don't overlook pregnancy: Even with regular DMPA use, rule out pregnancy if clinically indicated, especially with new-onset symptoms 2

4. Consider recent meningioma data: While primarily associated with prolonged use (>4 years) or initiation after age 31, recent evidence shows DMPA increases meningioma risk (RR 2.43) 6, 7. Persistent severe headaches warrant heightened vigilance, though the absolute risk remains low (NNH = 1152).

Documentation and Follow-Up

Document the specific symptoms, their severity, timing relative to injection, and your clinical assessment. If continuing DMPA, schedule follow-up within 3 months to reassess. If transitioning methods, ensure contraceptive coverage during the transition period and counsel on backup methods as needed 2.

The key principle: Prioritize the patient's quality of life and safety over method continuation. DMPA is highly effective, but only if the patient can tolerate it and continues using it.